Circulating urotensin II levels in moderate to severe congestive heart failure: Its relations with myocardial function and well established neurohormonal markers

Peptides

Volumn 27, Issue 6, 2006, Pages 1527-1531

  Gruson, D ^a   Rousseau, M F ^a   Ahn, S A ^a   van Linden, F ^a   Ketelslegers, J M ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Congestive heart failure; Neurohormonal markers; Urotensin II

Indexed keywords

BIG ENDOTHELIN 1; BIOCHEMICAL MARKER; BRAIN NATRIURETIC PEPTIDE; NEUROHORMONE; UROTENSIN II;

ADULT; AGED; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

AGED; FEMALE; HEART FAILURE, CONGESTIVE; HEART VENTRICLES; HORMONES; HUMANS; MALE; MIDDLE AGED; MYOCARDIUM; NEUROTRANSMITTER AGENTS; PEPTIDES, CYCLIC; RADIOIMMUNOASSAY; UROTENSINS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33746276776     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2005.11.019     Document Type: Article

References (23)

1. Ames R.S., Sarau H.M., Chambers J.K., Willette R.N., Aiyar N.V., Romanic A.M., et al. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 401 (1999) 282-286
2. Bottrill F.E., Douglas S.A., Hiley C.R., and White R. Human urotensin-II is an endothelium-dependent vasodilator in rat small arteries. Br J Pharmacol 130 (2000) 1865-1870
3. Douglas S.A., Ashton D.J., Sauermelch C.F., Coatney R.W., Ohlstein D.H., Ruffolo M.R., et al. Human urotensin-II is a potent vasoactive peptide: pharmacological characterization in the rat, mouse, dog and primate. J Cardiovasc Pharmacol 36 (2000) S163-S166
4. Douglas S.A., Tayara L., Ohlstein E.H., Halawa N., and Giaid A. Congestive heart failure and expression of myocardial urotensin II. Lancet 359 (2002) 1990-1997
5. Dschietzig T., Bartsch C., Pregla R., Zurbrugg H.R., Armbruster F.P., Richter C., et al. Plasma levels and cardiovascular gene expression of urotensin-II in human heart failure. Regul Pept 110 (2002) 33-38
6. Gray G.A., Jones M.R., and Sharif I. Human urotensin II increases coronary perfusion pressure in the isolated rat heart: potentiation by nitric oxide synthase and cyclooxygenase inhibition. Life Sci 69 (2001) 175-180
7. Hassan G.S., Chouiali F., Saito T., Hu F., Douglas S.A., Ao Z., et al. Effect of human urotensin-II infusion on hemodynamics and cardiac function. Can J Physiol Pharmacol 81 (2003) 125-128
8. Lapp H., Boerrigter G., Costello-Boerrigter L.C., Jaekel K., Scheffold T., Krakau I., et al. Elevated plasma human urotensin-II-like immunoreactivity in ischemic cardiomyopathy. Int J Cardiol 94 (2004) 93-97
9. Ng L.L., Loke I., O'Brien R.J., Squire I.B., and Davies J.E. Plasma urotensin in human systolic heart failure. Circulation 106 (2002) 2877-2880
10. Onan D., Pipolo L., Yang E., Hannan R.D., and Thomas W.G. Urotensin II promotes hypertrophy of cardiac myocytes via mitogen-activated protein kinases. Mol Endocrinol 18 (2004) 2344-2354
11. Pacher R., Stanek B., Hulsmann M., Koller-Strametz J., Berger R., Schuller M., et al. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol 27 (1996) 633-641
12. Richards A.M., Nicholls M.G., Lainchbury J.G., Fisher S., and Yandle T.G. Plasma urotensin II in heart failure. Lancet 360 (2002) 545-546
13. Russell F.D. Emerging roles of urotensin-II in cardiovascular disease. Pharmacol Ther 103 (2004) 223-243
14. Russell F.D., Meyers D., Galbraith A.J., Bett N., Toth I., Kearns P., et al. Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure. Am J Physiol Heart Circ Physiol 285 (2003) H1576-H1581
15. Russell F.D., Molenaar P., and O'Brien D.M. Cardiostimulant effects of urotensin-II in human heart in vitro. Br J Pharmacol 132 (2001) 5-9
16. Schoonjans F., Zalata A., Depuydt C.E., and Comhaire F.H. MedCalc: a new computer program for medical statistics. Comput Methods Programs Biomed 48 (1995) 257-262
17. Stirrat A., Gallagher M., Douglas S.A., Ohlstein E.H., Berry C., Kirk A., et al. Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries. Am J Physiol Heart Circ Physiol 280 (2001) H925-H928
18. Thanassoulis G., Huyhn T., and Giaid A. Urotensin II and cardiovascular diseases. Peptides 25 (2004) 1789-1794
19. Tzanidis A., Hannan R.D., Thomas W.G., Onan D., Autelitano D.J., See F., et al. Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy. Circ Res 93 (2003) 246-253
20. Van Beneden R., Gurne O., Selvais P.L., Ahn S.A., Robert A.R., Ketelslegers J.M., et al. Superiority of big endothelin-1 and endothelin-1 over natriuretic peptides in predicting survival in severe congestive heart failure: a 7-year follow-up study. J Card Fail 10 (2004) 490-495
21. Zhang A.Y., Chen Y.F., Zhang D.X., Yi F.X., Qi J., Andrade-Gordon P., et al. Urotensin II is a nitric oxide-dependent vasodilator and natriuretic peptide in the rat kidney. Am J Physiol Renal Physiol 285 (2003) F792-F798
22. Zhang Y., Li J., Cao J., Chen J., Yang J., Zhang Z., et al. Effect of chronic hypoxia on contents of urotensin II and its functional receptors in rat myocardium. Heart Vessels 16 (2002) 64-68
23. Zou Y., Nagai R., and Yamazaki T. Urotensin II induces hypertrophic responses in cultured cardiomyocytes from neonatal rats. FEBS Lett 508 (2001) 57-60